5254 studies found for:    vaccination
Show Display Options
Rank Status Study
21 Terminated Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients
Condition: Malignant Melanoma Stage IV
Interventions: Biological: DC Vaccine & Cyclophosphamide;   Biological: DC Vaccine & Placebo
22 Withdrawn Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1
Condition: Influenza
Interventions: Biological: Vaccine Sanofi A(H1N1) 15 ug & trivalent;   Biological: Vaccine Sanofi (H1N1) 15 ug.nonadyuvante;   Biological: Vaccine Sanofi A(H1N1) 7.5 ug
23 Active, not recruiting High Dose Influenza Vaccine in Nursing Homes
Condition: Influenza
Interventions: Biological: HD Vaccine;   Biological: SD Vaccine;   Biological: Free Staff Vaccine;   Biological: No Free Staff Vaccine
24 Completed Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants
Condition: Infection, Viral, Enterovirus
Interventions: Biological: 100U EV71 vaccine with adjuvant;   Biological: 200 U EV71 vaccine with adjuvant;   Biological: 400U EV71 vaccine with adjuvant;   Biological: 200U EV71 vaccine without adjuvant;   Biological: Placebo
25 Completed Safety and Immunogenicity of Influenza H9 Vaccine in Humans
Condition: Influenza
Interventions: Biological: H9N2 whole virus vaccine, IM, 1.5microg;   Biological: H9N2 whole virus vaccine, IM, 5microg;   Biological: H9N2 whole virus vaccine vaccine, IM, 15microg;   Biological: H9N2 whole virus vaccine, IM, 45microg;   Biological: H9N2 whole virus vaccine, alum, IM, 1.5microg;   Biological: H9N2 whole virus, alum, IM, 5microg;   Biological: H9N2 vaccine, whole virus, alum, IM, 15 microg;   Biological: H9N2 vaccine, whole virus, alum, IM, 45microg;   Biological: H9N2 virosome vaccine, IM, 1.5microg;   Biological: H9N2 virosomal vaccine, IM, 5microg;   Biological: H9N2 virosomal vaccine, IM, 15microg;   Biological: H9N2 virosomal vaccine, IM, 45microg;   Biological: H9N2 whole virus vaccine, ID, 5microg;   Biological: H9N2 whole virus vaccine, ID, 15microg
26 Completed
Has Results
Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old
Condition: Influenza
Interventions: Biological: Lot A of Influenza virus vaccine;   Biological: Lot B of Influenza virus vaccine;   Biological: Lot C of Influenza virus vaccine;   Biological: Comparator influenza virus vaccine;   Biological: All 3 consecutive lots of influenza virus vaccine pooled
27 Completed
Has Results
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
Condition: Pneumococcal Infections
Interventions: Biological: 13-valent pneumococcal conjugate vaccine (13vPnC);   Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
28 Completed
Has Results
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
Conditions: HIV-1;   HIV Infections
Interventions: Other: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine;   Biological: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose);   Biological: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine
29 Recruiting Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
Conditions: Meningitis;   Meningococcal Meningitis;   Meningococcal Infections
Interventions: Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine;   Biological: Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197Conjugate Vaccine;   Biological: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed;   Biological: GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
30 Completed A Clinical Trial With Influenza A/H1N1 Vaccines
Condition: Influenza
Interventions: Biological: split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose;   Biological: split-virion, adjuvanted H1N1 vaccine of 15 μg per dose;   Biological: split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose;   Biological: split-virion, non-adjuvanted H1N1 vaccine of 30 μg per dose;   Biological: whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose;   Biological: whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose;   Biological: placebo control
31 Active, not recruiting Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.
Conditions: Diphtheria;   Tetanus;   Pertussis
Interventions: Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL);   Biological: DT vaccine (Diphtheria and Tetanus Combined Vaccine, Adsorbed);   Biological: Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed)
32 Active, not recruiting Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Conditions: Childhood Cancer;   Multiple Diseases
Interventions: Biological: Immunization Schedule patients <7 years.;   Biological: Immunization Schedule patients > or = to 7 years and <11 years of age;   Biological: Immunization Schedule patients > or = to 11 years of age
33 Completed The Efficacy of Influenza Vaccination in Patients With Coronary Artery Diseases
Conditions: Coronary Artery Diseases;   Myocardial Infarction;   Stable Angina
Interventions: Biological: influenza vaccine;   Biological: placebo for influenza vaccine
34 Completed Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers
Condition: Healthy Volunteers
Interventions: Biological: rFIV vaccine;   Biological: rF1V vaccine;   Biological: rF1V vaccine 160 mcg given on Study Days 0, 56, 182
35 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
Condition: Meningitis, Meningococcal
Interventions: Biological: Meningococcal ACWY Conjugate Vaccine;   Biological: DTaP-IPV-HBV;   Biological: Hib;   Biological: Rotavirus;   Biological: Pneumococcal 7-valent Conjugate Vaccine;   Biological: HAV;   Biological: MMR-V;   Biological: DTaP
36 Active, not recruiting A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: rMenB + OMV vaccine;   Biological: rMenB + OMV NZ vaccine; Meningococcal C oligosaccharide conjugated vaccine; Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed;   Biological: Meningococcal C oligosaccharide conjugated vaccine; Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed
37 Completed Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine
Condition: Dengue
Interventions: Biological: TetraVax-DV Vaccine-Admixture 1;   Biological: TetraVax-DV Vaccine-Admixture 2;   Biological: TetraVax-DV Vaccine-Admixture 3;   Biological: TetraVax-DV Vaccine-Admixture 4;   Biological: Placebo;   Biological: TetraVax-DV Vaccine-Admixture 5
38 Active, not recruiting Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Conditions: Meningococcal Meningitis;   Meningococcal Infections
Interventions: Biological: Test Vaccine;   Biological: US Licensed Vaccine
39 Recruiting Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
Conditions: HPV16+;   Cervical Intraepithelial Neoplasia (CIN 2/3)
Interventions: Biological: DNA vaccination;   Device: Gene gun vaccine;   Biological: intramuscular vaccination;   Biological: intra-lesional vaccine administration;   Procedure: therapeutic resection of the lesion
40 Completed Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults
Condition: Hepatitis A
Interventions: Biological: Inactivated HAV vaccine;   Biological: Live attenuated HAV vaccine

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years